TransMega™ Lentiviral & Adenoviral Transduction Reagent (XS-1225-HM1)

Name: TransMega™ Lentiviral & Adenoviral Transduction Reagent
SKU: XS-1225-HM1
Rating: 5 (1 reviews)

Online Inquiry Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

TransMega™ Lentiviral & Adenoviral Transduction Reagent is an innovative chemical formulation designed to enhance lentiviral and adenoviral transduction efficiency in activated T cells. When used in combination with specific proteins, it significantly boosts gene delivery. It promotes T cell expansion while maintaining higher cell survival rates. Additionally, this product is safe for T cells and eliminates the need to replace the media after infection.

Specific Inquiry

Add to Cart

Specifications

Applications
T cell transduction; T cell expansion; Process development and scale-up; Cell and gene therapy research

Storage
Store at -20° C

Shelf Life
24 months

Features
User-Friendly: Direct addition to culture media for streamlined workflow.
Biocompatible: Safe for T cells; no need to replace media after infection.
Universal: Effective with all packaged lentivirus types.
Expansion-Compatible: Preserves T-cell proliferation and viability.
Adaptable: Enhances transduction efficiency across different T-cell activation methods.

Protocol
Protocol 1
Step 1: Thaw cells (Pan-T cells or PBMCs)
Step 2: Activate cells in 1x10e6/ml using anti-CD3 antibody, magnetic beads, or transduction enhancement reagent.
Step 3:
1. Coat the plate with extracellular matrix protein and incubate for 2 hours at room temperature.
2. Block the coated plate with an appropriate volume of sterile 2% BSA in PBS for 30 minutes, then remove the blocking buffer and rinse with PBS to keep the wells moist.
3. Remove the activation reagent and prepare T cells at 1 × 10⁶/mL.
4. Add the appropriate MOI of lentivirus or retrovirus and this product (1000×) to the T cells.
5. Transfer T cells with virus and this product to coated wells.
Step 4: Analyze transduction efficiency by flow cytometry.
(Total cycle time: approximately 7 days)

Protocol 2
Step 1: Thaw and activate Pan-T cells or PBMCs at 1.5 × 10⁶/mL using anti-CD3 antibody, magnetic beads, or transduction enhancement reagent.
Step 2:
1. Coat the plate with extracellular matrix protein and incubate for 2 hours at room temperature.
2. Block the coated plate by adding an appropriate volume of sterile 2% BSA in PBS for 30 minutes. Remove the blocking buffer and rinse with PBS to keep the wells moist.
3. Add the appropriate MOI of lentivirus (or retrovirus) and this product (1000×) to the T cell mixture (0.5-1 × 10⁶/mL) with activation reagent.
4. Transfer the T cell, virus, and reagent mixture to the coated wells.
Step 3: Centrifuge to change the medium.
Step 4: Analyze transduction efficiency by flow cytometry.
(Total cycle time: approximately 6 days)

Shelf Life
24 months

Customer Reviews and Q&As

There are currently no customer reviews or questions for TransMega™ Lentiviral & Adenoviral Transduction Reagent (XS-1225-HM1). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Key Updates

NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER

NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION

Novel Solution. (Creative Biolabs Authorized)

NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY

New Technology. (Creative Biolabs Authorized)

NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION